Monthly Archives: September 2012

Scientific Reproducibility: Begley’s Six Rules
September 26, 2012

The lack of robust reproducibility in the scientific literature is both shocking and troubling, and has been a widely covered topic over the past couple years. One of the earliest blogs here at LifeSciVC was on the dirty secret that

6 Comments

New Biotech Corporate Structures: Possible Alternatives For Discovery Platforms and Product Financings
September 18, 2012

Not a biotech conference goes by these days without a discussion about new models for financing or exiting companies, and BioPharm America in Boston this week is no different.  I’m on a panel discussing the topic on Wednesday afternoon. New

1 Comment

Biotech M&A Earnout Payments, Data Redux
September 12, 2012

Earnout deals are back in the news with an interesting report from Shareholder Representative Services, or SRS, a firm who specializes in working for the selling party’s shareholders to follow up post-acquisition to ensure that escrows are paid, diligence is

Leave a comment

Biotech Scientific Advisory Boards: What Works, What Doesn’t
September 10, 2012

Almost every biotech has a Scientific Advisory Board, but few use them particularly well.   Although SABs can be hugely valuable in helping shape a program or portfolio, or raising the visibility of a startup, they can also be a colossal

5 Comments